Effect of the combination of BCc1 & Hep-S on hospitalized COVID-19 patients

INTERVENTION: Intervention 1: Intervention group 1 – Medicine: chelated mixture named BCc1. Number & content: a 250 cc bottle containing 200 cc medicine in the form of syrup. Chemical mixture: polymerized organic acid using nanochelating technology. Density: 500 mg of chelated mixture per 2 cc. Consumption dose: 3 servings per day (4 cc per serving). Direction for use: the consumption dose per serving should be diluted in 250 cc of water and consumed orally. Equipment: no special equipment is required. Patients will be provided with the medicine placed in 250 cc bottles along with a sterilized 15 cc falcon tube to measure the consumption dose. Consumption duration: hospitalization period. Manufacturing company: laboratory of Sodour Ahrar Shargh Knowledge‐based Company. Intervention 2: Intervention group 2 – Medicine: chelated selenium mixture named Hep‐s. Number & content: a 250 cc bottle containing 200 cc medicine in the form of syrup. Chemical mixture: polymerized organic acid using nanochelating technology. Density: 500 µg of chelated selenium mixture per 2 cc. Consumption dose: 3 servings per day. 12 cc on the first 3 days and 6 cc from day 4 onwards. Direction for use: the consumption dose per serving should be diluted in 250 cc of water and consumed orally. Equipment: no special equipment is required. Patients will be provided with the medicine placed in 250 cc bottles along with a sterilized 15 cc falcon tube to measure the consumption dose. Consumption duration: hospitalization period. Manufacturing company: laboratory of Sodour Ahrar Shargh Knowledge‐based Company. Intervention 3: Intervention group 3 – Medicine: a package of BCc1 & Hep‐s. Number & content: two separate 250 cc bottles for BCc1 & Hep‐s, each containing 200 cc medicine in the form of syrup. Chemical mixture: p CONDITION: COVID‐19. ; COVID‐19, virus identified U07.1 PRIMARY OUTCOME: Clinical indices. Timepoint: Before intervention, 3 & 6 days after intervention and before being released. Method of measurement: Questionnaire. CT scan images of the lungs. Timepoint: Before hospitalization & 2 weeks after. Method of measurement: CT scan images. CT scan of the lungs. Timepoint: Before the start of the intervention, before being released & 2 weeks after. Method of measurement: CT scan machine. Hospitalization period. Timepoint: Hospitalization period. Method of measurement: Counting hospitalization days. Mortality. Timepoint: Before and after being released. Method of measurement: Observation. INCLUSION CRITERIA: Hospitalized definite COVID‐19 patients diagnosed by PCR & CT scan of the lungs Patients' filling out a consent form Patients won't be discharged within 48 hrs Patients' conditions won't be improving within 48 hrs SECONDARY OUTCOME: CBC. Timepoint: Before intervention, 3 & 6 days after intervention and before being released. Method of measurement: Biochemical methods. CRP. Timepoint: Before intervention, 3 & 6 days after intervention and before being released. Method of measurement: Biochemical methods. ESR. Timepoint: Before intervention, 3 & 6 days after intervention and before being released. Method of measurement: Biochemical methods. Oxygen saturation in patients. Timepoint: Before intervention, every day after intervention and before being released. Method of measurement: Pulse oximetry. PCR test. Timepoint: Before intervention & before being released. Method of measurement: Molecular methods. SGOT & SGPT enzymes. Timepoint: Before intervention & before being released. Method of measurement: Biochemical methods.